Hidden Costs for Patients Starting a Specialty Drug Regimen

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Related Content:

InterviewsReimbursementSpecialty Pharmacy
Treatment with Ofatumumab Increases Number of Patients Who Achieve No Evidence of Disease Activity for MS
Bringing Oncology Pharmacy Leaders, Payers Together to Address Unmet Educational Needs in the Field
Oncology Overview: Sonidegib (Odomzo) for Locally Advanced Basal Cell Carcinoma